JP2012520085A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520085A5
JP2012520085A5 JP2011554275A JP2011554275A JP2012520085A5 JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5 JP 2011554275 A JP2011554275 A JP 2011554275A JP 2011554275 A JP2011554275 A JP 2011554275A JP 2012520085 A5 JP2012520085 A5 JP 2012520085A5
Authority
JP
Japan
Prior art keywords
sequence
polynucleotide
expression vector
cell
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011554275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012520085A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027365 external-priority patent/WO2010105277A1/en
Publication of JP2012520085A publication Critical patent/JP2012520085A/ja
Publication of JP2012520085A5 publication Critical patent/JP2012520085A5/ja
Pending legal-status Critical Current

Links

JP2011554275A 2009-03-13 2010-03-15 生物活性rnaの送達のための組成物及び方法 Pending JP2012520085A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16028709P 2009-03-13 2009-03-13
US16028809P 2009-03-13 2009-03-13
US61/160,287 2009-03-13
US61/160,288 2009-03-13
PCT/US2010/027365 WO2010105277A1 (en) 2009-03-13 2010-03-15 Compositions and methods for the delivery of biologically active rnas

Publications (2)

Publication Number Publication Date
JP2012520085A JP2012520085A (ja) 2012-09-06
JP2012520085A5 true JP2012520085A5 (enExample) 2013-02-21

Family

ID=42728852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011554275A Pending JP2012520085A (ja) 2009-03-13 2010-03-15 生物活性rnaの送達のための組成物及び方法

Country Status (8)

Country Link
US (2) US8569065B2 (enExample)
EP (1) EP2406379A4 (enExample)
JP (1) JP2012520085A (enExample)
KR (1) KR20110128345A (enExample)
CN (1) CN102625842A (enExample)
AU (1) AU2010223888A1 (enExample)
CA (1) CA2755245A1 (enExample)
WO (1) WO2010105277A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5863670B2 (ja) 2010-01-19 2016-02-17 ノースウェスタン ユニバーシティ 核酸および/または他の構成要素を含有している合成ナノ構造体
WO2011113054A2 (en) * 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
US9593347B2 (en) 2010-04-16 2017-03-14 University of Pittsburgh—of the Commonwealth System of Higher Education Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012159164A1 (en) * 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
KR20140123054A (ko) * 2011-12-23 2014-10-21 씨엘에스엔 래버러토리스, 인코퍼레이티드 생물학적 활성 rna의 전달을 위한 조성물 및 방법
WO2013101690A1 (en) * 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
US9909123B2 (en) * 2013-03-15 2018-03-06 Techulon Inc. Antisense molecules for treatment of Staphylococcus aureus infection
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
WO2015023797A1 (en) 2013-08-13 2015-02-19 Northwestern University Lipophilic nanoparticles for drug delivery
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
KR102490462B1 (ko) 2013-10-28 2023-01-19 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양분해성 hsv 벡터
WO2015120541A1 (en) * 2014-02-14 2015-08-20 Symvivo Corporation Nucleic acid vectors and uses thereof
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
EA201790802A1 (ru) 2014-10-06 2017-08-31 Экзикьюр, Инк. Соединения против tnf
US9816080B2 (en) * 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
ES2919953T3 (es) 2016-01-27 2022-07-29 Oncorus Inc Vectores víricos oncolíticos y usos de los mismos
US11639371B2 (en) * 2016-02-17 2023-05-02 The Chinese University Of Hong Kong Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases
WO2017161043A1 (en) 2016-03-16 2017-09-21 The J. David Gladstone Institutes Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
CN109983121A (zh) 2016-06-30 2019-07-05 昂克诺斯公司 治疗性多肽的假型化溶瘤病毒递送
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
WO2020010083A1 (en) * 2018-07-05 2020-01-09 The Regents Of The University Of California Compositions and methods for delivery of rna to a cell
JP2022550130A (ja) 2019-09-26 2022-11-30 プレジデント アンド フェローズ オブ ハーバード カレッジ 最小アレスチンドメイン含有蛋白質1(arrdc1)コンストラクト
WO2023244760A1 (en) * 2022-06-15 2023-12-21 Duke University Protein library display systems and methods thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585263A (en) 1994-05-20 1996-12-17 University Of Alabama At Birmingham Research Foundation Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US20040241845A1 (en) * 1998-05-22 2004-12-02 Luc Desgroseillers Mammalian staufen and use thereof
US6899871B2 (en) * 1998-10-01 2005-05-31 University Of Southern California Gene delivery system and methods of use
JP2002533128A (ja) * 1998-12-31 2002-10-08 アドバンスド リサーチ アンド テクノロジー インスティテュート アデノ随伴ウイルス2による感染のためのコレセプターとしてのヒト線維芽細胞増殖因子レセプター1
AU2001294872A1 (en) 2000-09-28 2002-04-08 Cellomics, Inc. Methods and reagents for live-cell gene expression quantification
CU23225A1 (es) * 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
US20040005593A1 (en) * 2002-03-06 2004-01-08 Rigel Pharmaceuticals, Inc. Novel method for delivery and intracellular synthesis of siRNA molecules
US20050074865A1 (en) * 2002-08-27 2005-04-07 Compound Therapeutics, Inc. Adzymes and uses thereof
JP2006512906A (ja) 2002-09-28 2006-04-20 マサチューセッツ インスティチュート オブ テクノロジー インフルエンザ治療剤
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
CN101415816A (zh) 2006-02-02 2009-04-22 雷格内泰克公司 表征生物活性化合物的方法
JP2009532017A (ja) * 2006-02-10 2009-09-10 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達
US9085778B2 (en) * 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
CN100549179C (zh) * 2006-08-07 2009-10-14 汪运山 胃癌靶向AFP基因的siRNAs表达载体及其用途
US20100112638A1 (en) * 2007-02-15 2010-05-06 Cornelis Maria Jacobus Sagt Recombinant host cell for the production of a compound of interest
EP3023495B1 (en) 2010-02-24 2019-05-08 Arrowhead Pharmaceuticals, Inc. Compositions for targeted delivery of sirna

Similar Documents

Publication Publication Date Title
JP2019524140A5 (enExample)
JP2018532705A5 (enExample)
JP2022516130A5 (enExample)
JP2018528237A5 (enExample)
RU2013152648A (ru) Аденовирус обезьян и гибридные аденовирусные векторы
HRP20230150T1 (hr) Konstrukcija kimernog antigenskog receptora koji cilja cd20 antigen i identifikacija aktivnosti njegovih inženjerskih t-stanica
EP2852407A1 (fr) Cassettes d'expression procaryotes régulées par le stress.
JP2011062217A5 (enExample)
WO2008084115A3 (en) Lactococcus promoters and uses thereof
JP2013530689A5 (enExample)
JP2020523983A5 (enExample)
JP2009528843A5 (enExample)
JP2011520424A5 (enExample)
JP2016503434A5 (enExample)
JP2023504826A5 (enExample)
CN116218904B (zh) 一种可提高工程化细胞外泌体中特定核酸分子载量的方法及其应用
CN109929865A (zh) 基于gal4-uas系统的crispr辅助反式增强子激活基因表达的方法及其应用
CN103266127B (zh) 一种电击转化枯草芽孢杆菌的方法
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
CN102702335A (zh) 重组转录激活子样效应因子、转录激活子样效应因子核酸酶及其编码基因及应用
RU2008153051A (ru) Способ направленной доставки днк в опухолевые и стволовые клетки
CN102753687B (zh) 用于遗传转化藻类的新型启动子
CN112888712A (zh) 工程化的微生物及其制造和使用方法
AR102762A1 (es) Secuencia de oligonucleótidos para uso en ingeniería de rutas metabólicas
CA2752947A1 (en) Foxp1 splice variants and methods and uses thereof